Table 1.
Patient characteristicsTables.
| Patient characteristics | ||
|---|---|---|
| Sex (male; female) | 114; 216 | |
| baseline | follow-up | |
| Age (years; mean ± SD; range) | 38.5 ± 9.7; 19–65 | 40.5 ± 9.8; 21–67 |
| Disease duration (years; mean ± SD; range) | 1.6 ± 3.3; 0–21.2 | 3.7 ± 3.3; 1.6 – 23.6 |
| Disease course (CIS; RRMS; SPMS) | 25; 305; 0 | 7; 321; 2 |
| Disease modifying drugs | none 280; DMF 3; GA 12; IFN 32; NTZ 2, study medication 1 | none 83; DMF 27 FTY 14; GA 68; IFN 114; NTZ 20, TFN 2; RTX 1; study medication 1 |
| EDSS (N; median; range) | 284; 1.5; 0–6.0 | 321; 1.5; 0–6.5 |
CIS, clinically isolated syndrome; DMF, dimethyl fumarate; EDSS, Expanded Disability Status Scale; FTY, fingolimod; GA, glatiramer acetate; IFN, beta interferon; NTZ, natalizumab; RRMS, relapsing remitting multiple sclerosis; RTX, rituximab; SD, standard deviation; SPMS, secondary progressive multiple sclerosis; TFN, teriflunomide.